Therefore, lenvatinib, one of the most potent VEGFR inhibitors, could potentiate EPO production by HCC cells subject to hypoxic-like conditions and explain the Hb/Ht increase. The gene discussed is GSTM1; the disease is hepatocellular carcinoma.